Q: Good Morning
Since November 29, 2016 there were no insider buyers in this Company just sellers. Furthermore, both the CEO and CFO reduced their positions by 2,000,000 shares each during the last year.
Q: Savaria has announced a $1.1m contract in China. The share price has responded quite well. A $1.1m contract is not “huge” but if they do a good job executing it doors may open.
Q: I've held Cynosure (CYNO) for a few years and it recently received an all cash offer for $66 a share; however, now some law firm has come out questioning "whether the Company’s Board of Directors failed to satisfy their duties to shareholders, including whether the Board adequately pursued alternatives to the acquisition and whether the Board obtained the best price possible for the Company’s shares of common stock."
The stock went has high as $66.65 on the news but is currently hovering just above $66.
In these types of situations does this often result in a higher offer? I am tempted to hold and see what happens if there is essentially no risk but I would also like to sell now to get the cash. What would you do?
Q: Just wandering if you had any idea why there was a sharp pullback today in the face of a fairly decent quarterly report.Also would you look at adding now,I have a .75% position currently in the stock thanks
Q: What do you think now of Valiant Pharmaceuticals?
It is at its lowest 52 week low. Its market cap is still 5.35 Billion.
Is it recommended for a buy and hold for at least a year?
Q: I've enjoyed a quick run-up on TH. It now represents an 8% portfolio weight. My questions is two parts. First, could you comment on their prospects? Their earnings should be growing and they are adding a drug to their offering. As a thing trader, there could be a big run-up as the story gains traction.
Second, in a case like this where there is a quick run-up and the portfolio weighting becomes large, when is it time to trim? It seems to me that using portfolio weight as your only guide could mean missing big gains if you're early on a good company.
Q: Hello. How does the 5I team rate the quality of the management of PLI? Has PLI also given any indication of product releases for 2017 given that their drug tests favourably in all tests and has orphan drug status?
Thank You
Clarence
Q: Thinking of this one in replacement of GILD that i sold 2 weeks ago. low p/e and peg, nice dividend but high debt.Argus and S&P by applying comp p/e come up with a target of 84$. Does it deserve the p/e or cheap for a reason?
What is your view on this one ?
Any suggestion ?
(like everybody else: I know you don't cover US stocks... bla bla bla)
Thanks much!
Q: I was asked to review my sons portfolio and he is a ETF investor mainly. I have a concern with the very high MER of 3.76% current for healthcare Leader income ETF It has a high yield (8.4%) that I think is tempting him but Brand leader fund by the same firm has a mer of 1.44 %. Why the big difference. I see the hhl is advertised and promoted heavily on BNN. Are they charging fund holders for their promo on a under preforming fund? I found a great site The Wealth Game (wealthgame.ca) that lets you calculate the true cost over time of fees. It can be an eye opener for younger people with longer time horizons that are sucked into what they may think are low fees such as 2 or 3 percent. Your views please.